Kumar, S K http://orcid.org/0000-0001-5392-9284
Dimopoulos, M A
Kastritis, E
Terpos, E
Nahi, H
Goldschmidt, H
Hillengass, J
Leleu, X
Beksac, M http://orcid.org/0000-0003-1797-8657
Alsina, M
Oriol, A
Cavo, M
Ocio, E M
Mateos, M V
O'Donnell, E K
Vij, R
Lokhorst, H M
van de Donk, N W C J
Min, C
Mark, T
Turesson, I
Hansson, M http://orcid.org/0000-0002-7715-4548
Ludwig, H
Jagannath, S
Delforge, M
Kyriakou, C
Hari, P
Mellqvist, U
Usmani, S Z
Dytfeld, D
Badros, A Z
Moreau, P
Kim, K http://orcid.org/0000-0001-8986-8436
Otero, P R
Lee, J H
Shustik, C
Waller, D
Chng, W J
Ozaki, S
Lee, J-J
de la Rubia, J
Eom, H S
Rosinol, L
Lahuerta, J J
Sureda, A
Kim, J S
Durie, B G M
Article History
Received: 1 February 2017
Revised: 4 April 2017
Accepted: 20 April 2017
First Online: 12 May 2017
Competing interests
: SKK: research funding (Abbvie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda) and honoraria (Skyline Diagnostics); MAD: honoraria (Celgene, Janssen, Amgen and Takeda); ET: research funding and honoraria (Amgen, Celgene and Janssen), and honoraria (Novartis, GSK, Bristol Myers Squibb and Takeda); HG: research funding, advisory board and honoraria (Janssen, Celgene, Novartis and BMS), research funding and honoraria (Chugai), and advisory boards (Amgen and Takeda); JH: consultancy, honoraria and advisory board (Amgen), honoraria and advisory board (Janssen, Celgene and Novartis), honoraria (Bristol Myers Squibb) and research funding (Sanofi); MB: speakers bureau and advisory board (Celgene, Janssen-Cilag, Amgen, Novartis, Takeda and Bristol Myers Squibb); MA: speakers bureau (Janssen); AO: advisory board and consultancy (Amgen and Janssen), and consultancy (Takeda); MVM: honoraria and advisory board (Janssen, Celgene, Takeda and Amgen); RV: research support and consultancy/honoraria (Amgen, Celgene and Takeda), and consultancy/honoraria (Bristol Myers Squibb, Janssen, Karyopham and Abbvie); H Lokhorst: research funding and advisory board (Janssen), and research funding (Genmab); NvdD: research funding (Janssen, Celgene, Amgen and BMS) and advisory board (Janssen, Celgene, Amgen, BMS and Novartis); TM: research funding (Amgen and Celgene); MH: advisory board (Celgene, Janssen, Amgen and Takeda); H Ludwig: speakers bureau (Celgene, Takeda, Amgen and Janssen-Cilag), advisory board (Celgene, Amgen, Janssen-Cilag, AbbVie and Bristol Myers Squibb) and research funding (Takeda and Amgen); MD: consultancy (Amgen, Bristol Myers Squibb, Celgene, Janssen and Takeda) and research funding (Celgene and Janssen); U-HM: advisory board (Amgen and Takeda) and honoraria (Amgen, Celgene, Takeda, Mundipharma, Janssen and Novartis); SZU: advisory board (Amgen, Celgene and Skyline Diagnostics), speakers bureau (Amgen, Celgene and Takeda) and research funding (Amgen, Celgene, Janssen, Sanofi, Pharmacyclics, Array Biopharma and Takeda); PM: advisory board (Celgene, Takeda, Janssen, Novartis and Amgen); LR: honoraria (Janssen and Celgene); all the other authors declare no conflicts of interest.